2020
DOI: 10.1111/cup.13638
|View full text |Cite
|
Sign up to set email alerts
|

Myxoinflammatory fibroblastic sarcoma: A rare case affecting only the dermis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 9 publications
0
2
0
Order By: Relevance
“…This case, like the majority of these tumours demonstrate strong immunoreactivity for vimentin and D2‐40 1,3 . However, the absence of distinctive immunohistochemical markers makes it difficult to differentiate them from other similar soft tissue tumours which resemble MIFS in terms of clinical presentation and histopathological findings, including hemosiderotic fibrolipomatous tumour and pleomorphic hyalinizing angiectatic tumour 4 …”
Section: Figmentioning
confidence: 74%
See 1 more Smart Citation
“…This case, like the majority of these tumours demonstrate strong immunoreactivity for vimentin and D2‐40 1,3 . However, the absence of distinctive immunohistochemical markers makes it difficult to differentiate them from other similar soft tissue tumours which resemble MIFS in terms of clinical presentation and histopathological findings, including hemosiderotic fibrolipomatous tumour and pleomorphic hyalinizing angiectatic tumour 4 …”
Section: Figmentioning
confidence: 74%
“…1,3 However, the absence of distinctive immunohistochemical markers makes it difficult to differentiate them from other similar soft tissue tumours which resemble MIFS in terms of clinical presentation and histopathological findings, including hemosiderotic fibrolipomatous tumour and pleomorphic hyalinizing angiectatic tumour. 4 Due to MIFS high local recurrence rate and associated morbidity, complete margin-negative excision is the most evidenced approach to reduce this rate. 5,6 There might be a role of pre-operative radiation therapy in deep and high-grade extremity soft tissue sarcomas.…”
mentioning
confidence: 99%